NCT03529422 2025-07-20Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHNUNC Lineberger Comprehensive Cancer CenterPhase 2 Active not recruiting18 enrolled 10 charts
NCT03737968 2023-03-21Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.Yonsei UniversityPhase 2 Unknown48 enrolled